8-K filing — Tempus AI, Inc. (TEM)
Filed: 2026-11-18 AccNo: 0001193125-26-466240 Size: 212 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Tempus AI has announced an expansion of its existing data and sequencing collaboration with Remix Therapeutics.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-18 AccNo: 0001193125-26-466240 Size: 212 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Tempus AI announced that six of its research abstracts have been accepted for presentation at the upcoming 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting.
Tempus AI is providing its technology, including the Olivia personal health concierge app, to support the REALworld: AML initiative focused on pediatric acute myeloid leukemia.
Tempus AI has entered a collaboration with the SOTERIA Precision Medicine Foundation to provide genomic sequencing and AI-driven insights to active-duty service members and veterans.